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Abstract
Available evidence suggests that both hydrostatic and osmotic forces are important in the
development of acute respiratory distress syndrome (ARDS) or, more broadly, acute lung
injury (ALI). More than 80% of ARDS patients in a large-scale randomized controlled trial
(RCT) exhibited, at least intermittently, pulmonary artery wedge pressures (PAWP) above
18mmHg. Retrospective analyses have shown that PAWP elevation is associated with
increased mortality. Reduction in serum total protein (STP) has been shown, in a recent
retrospective analysis of data from a sepsis patient population with a high frequency of
ARDS, to be highly predictive of positive fluid balance, weight gain, development of ARDS,
prolonged mechanical ventilation, and mortality. These findings suggest that therapy with
diuretics and colloids might be of benefit in the prevention or treatment of ALI. A prospective
RCT was designed and conducted to evaluate combination therapy with furosemide and
albumin over a 5-day period in 37 ALI patients. Both mean serum albumin and mean STP
increased promptly and substantially in furosemide + albumin recipients. The furosemide +
albumin group also achieved a mean weight loss of 10kg by the end of the treatment phase,
and their weight loss exceeded that of placebo patients throughout. Hemodynamics
improved in the treatment group during the 5-day protocol. Oxygenation, as assessed by the
ratio between the fraction of inspired oxygen and the partial pressure of oxygen in arterial
blood (PaO2/FiO2), was significantly higher within 24h after commencement of treatment in
the furosemide + albumin than the placebo group. No clinically important adverse effects of
furosemide + albumin therapy were encountered. These results provide evidence that
combined therapy with furosemide and albumin is effective in augmenting serum albumin
and STP levels, promoting weight loss, and improving oxygenation and longer-term
hemodynamic stability. Although mortality did not differ between groups, the RCT showed a
trend toward reduced duration of mechanical ventilation and length of stay in the intensive
care unit in patients receiving furosemide + albumin. The findings of the RCT further
highlight the importance of both hydrostatic and osmotic forces in hypoxemic respiratory
failure, a subject that requires further investigation.
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ALI = acute lung injury; ARDS = acute respiratory distress syndrome; ICU = intensive care unit; PaO2/FiO2 = ratio between the fraction of inspired
oxygen and the partial pressure of oxygen in arterial blood; PAWP = pulmonary artery wedge pressures; PEEP = positive end-expiratory pressure;
RCT = randomized controlled trial; STP = serum total protein.
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Introduction
Both hydrostatic and osmotic forces are at play in the
development of ARDS or, more broadly, ALI. There could
consequently be a potential clinical role for diuretic and
colloid therapy in patients at risk for ALI. This potential role
has been investigated in a recent randomized controlled
clinical trial.
Hydrostatic forces in ALI
Hydrostatic pressure is a key contributor to the formation
of edema regardless of the integrity of the capillary barrier,
although it exerts an exaggerated effect in states of
increased capillary permeability, which is a pathogno-
monic hallmark of ARDS or ALI. One exclusionary compo-
nent of the consensus conference definition for ALI and
ARDS is PAWP >18mmHg [1]. PAWP, nevertheless, at
least intermittently exceeded 18mmHg in more than 80%
of patients enrolled in a large-scale RCT of patients with
ARDS [2]. Furthermore, mortality risk is known to be
increased in ARDS patients with elevated PAWP [3,4].
The mortality rate was thus greater than 50% in patients
with PAWP consistently above 18mmHg, compared with
approximately 30–35% in patients without such persistent
PAWP elevation.
Retrospective observations have similarly revealed an asso-
ciation between PAWP reduction and improved survival in
ARDS patients [5]. The survival rate was nearly three-fold
higher among patients experiencing a >25% decline in
PAWP compared with patients who did not. In a random-
ized prospective trial of patients with pulmonary edema, a
fluid restrictive strategy was effective in reducing extra-
vascular lung water, days of mechanical ventilator support
and length of intensive care unit (ICU) stay, while resulting
in an encouraging trend towards reduced mortality [6].
Loop diuretics such as furosemide serve as first-line
therapy for renal insufficiency, nephrotic syndrome and
congestive heart failure, and second-line treatment in cir-
rhosis [7]. The role of loop diuretics in patients with ALI
remains to be defined. Most ARDS patients in one small-
scale prospective study reported over 20 years ago
responded favorably to diuretic therapy in conjunction with
positive end-expiratory pressure (PEEP) £20cmH2O [8].
Improvements were observed in static compliance of the
respiratory system, arterial oxygen tension and urine
output. There is hence suggestive, although limited,
evidence that interventions to reduce hydrostatic pressure
in the lung might lead to improved patient outcomes.
Osmotic forces in ALI
Based upon Starling’s equation, a reduced colloid
osmotic pressure gradient between the intravascular
space and interstitium can promote edema formation.
Re-establishment of this gradient through colloid adminis-
tration might serve to diminish edema; however, there is a
potential concern for exacerbating edema in states of
increased capillary permeability such as ALI. This concern
does not appear to be warranted in the absence of ele-
vated hydrostatic pressure, in that albumin infusion in
ARDS patients was found not to augment pulmonary
transmicrovascular flux of low or high molecular weight
solutes when colloid-related increases in pulmonary hydro-
static pressure were minimized [9].
Hypoproteinemia as risk factor for ARDS
Further insights into the role of plasma oncotic forces in
ALI have been provided by a retrospective analysis of data
from a large-scale multicenter RCT of ibuprofen treatment
in patients with sepsis [10]. This RCT, conducted from
1989 to 1995, involved 455 patients. Development of
ARDS occurred in 39% of these patients, and hypopro-
teinemia was documented in 92% of patients in this group.
Reduction in STP (ie in the primary determinant of serum
colloid osmotic pressure) was found, based upon regres-
sion analysis of the study database, to be highly predictive
of positive fluid balance, weight gain, development and
maintenance of ARDS, prolonged mechanical ventilation,
and mortality [11]. The incidence of ARDS was 22%
among normoproteinemic patients (STP ³6g/dl) com-
pared with 41 and 45% in patients with borderline (5g/dl
<STP<6g/dl) or severe (STP£5g/dl) hypoproteinemia,
respectively (P=0.0006). Whereas normoproteinemic
patients lost 3.6kg body weight on average during the
trial, their counterparts with borderline or severe hypopro-
teinemia gained 3.9 and 4.9kg, respectively (P=0.004).
Furthermore, the mortality rate of patients with borderline
(48%) or severe (45%) hypoproteinemia exceeded that of
normoproteinemic patients (14%) more than three-fold
(P=0.04). The clear association between hypoproteine-
mia and unfavorable clinical outcomes revealed by the ret-
rospective analysis suggests the possibility that patients
may derive benefit from interventions to increase serum
protein levels and, by inference, colloid osmotic pressure.
Furosemide and albumin in ALI: design of a RCT
The evidence already reviewed supports the concept that
reduction in hydrostatic forces and maintenance of normal
colloid osmotic pressure might improve clinical outcomes
in ALI patients. This evidence equally suggests that com-
bined diuretic and colloid therapy may benefit ALI patients.
Approximately 99% of furosemide in the circulation is
bound to albumin, and this binding facilitates delivery of
furosemide into the tubular lumen. Combined treatment
with furosemide and albumin was, in a recent RCT, signifi-
cantly more effective than either agent alone in promoting
volume excretion in patients with the nephrotic syndrome
[12]. In another recent RCT, a significantly higher propor-
tion of patients with cirrhosis and ascites responded to
co-administered furosemide and albumin with body weight
loss  ³2.5kg and/or resolution of ascites, as comparedhttp://ccforum.com/content/4/S2/S21
with patients receiving furosemide but not albumin [13].
Combination therapy with furosemide and albumin in a
rabbit model of experimentally induced lung injury reduced
lung water accumulation and alveolar–arterial oxygen
pressure difference, whereas monotherapy with either
agent alone was ineffective [14]. The potential utility of
diuretic and colloid therapy in patients with lung injury has
not, however, been the subject of clinical investigations to
date.
A RCT of ALI patients was designed and conducted to
test the hypotheses that albumin will enhance the diuretic
response to furosemide while avoiding potential adverse
effects of diuretic monotherapy, and that combined
albumin and furosemide therapy will improve respiratory
physiology [15]. Furosemide plus albumin was compared
with dual placebo under a randomized, double-blind proto-
col with the therapeutic goals of attaining net negative
fluid balance, weight loss, and an increase in serum pro-
teins over a period of 5 days. Outcome measures con-
sisted of vital signs and hemodynamics, respiratory
mechanics and oxygenation, blood chemistries, duration of
mechanical ventilation, and mortality.
Eligibility for study entry required a diagnosis of ALI or
ARDS by the American–European Consensus Conference
definition, with the additional requirements for mechanical
ventilation and hypoproteinemia. Patients were excluded
primarily for hemodynamic instability, renal or chronic
hepatic failure, or marked electrolyte abnormalities.
Patients randomized to the furosemide + albumin group
received furosemide by continuous intravenous infusion,
as titrated to achieve negative fluid balance, and 25g
albumin intravenously every 8h. Furosemide administration
was suspended in cases of hypotension or severe elec-
trolyte disturbances, and placebo was substituted for
albumin when STP exceeded the lower limit of normal.
Results of furosemide and albumin therapy in
ALI/ARDS
Patients were enrolled in the RCT over an 18-month
period, and the mean age of the 37 study patients was 42
years. The etiology of ALI was predominantly trauma
related, with common critical illnesses predisposing to
lung injury accounting for the remainder. No significant dif-
ferences existed between the 19 furosemide + albumin
treated patients and the 18 placebo patients in age, race,
gender, apportionment across etiologic categories or
baseline APACHE III score.
Both mean serum albumin and STP in the furosemide +
albumin group increased to a significantly greater extent
than that in placebo patients. The observed increase in
mean serum albumin among furosemide + albumin patients
was more than 1.5g/dl. Mean STP rose continuously in the
furosemide + albumin group to a plateau approaching the
lower limit of normal.
The furosemide + albumin group experienced a marked
decline in body weight over the follow-up period, and this
decline was significantly greater than that of the placebo
patients after day 1. Mean weight loss totaled 10kg by
day 5 in furosemide + albumin treated patients.
The pronounced changes in serum albumin, STP and
body weight associated with the furosemide + albumin
regimen were not accompanied by evidence of renal dys-
function, as judged by the lack of significant between-
group difference in blood urea nitrogen or creatinine.
These patients did, however, exhibit electrolyte effects
typical of diuretic treatment.
Mean arterial pressure in the furosemide + albumin group
had increased significantly by the conclusion of the 5-day
treatment period, while heart rate declined during the
same period. Placebo group hemodynamic status did not
depart appreciably from baseline.
No between-group or within-group differences were noted
in variables designed to detect alterations in respiratory
physiology. The baseline ratio between the fraction of
inspired oxygen and the partial pressure of oxygen in arter-
ial blood (PaO2/FiO2 ratio) in all patients was approxi-
mately 180mmHg, in conformity with the definition for
ARDS. Oxygenation, however, as assessed by PaO2/FiO2
ratio, was significantly increased by 40% in the
furosemide + albumin treated patients at 1–2 days, but
not in the placebo group.
Recipients of furosemide + albumin had shorter median
duration of mechanical ventilation and length of stay in the
ICU. In this comparatively small population, however,
these differences were not statistically significant. Three
patients died in each study group, and the mortality rate of
the furosemide + albumin group (16%) was similar to that
of the placebo group (17%).
Conclusion
Critically ill patients have difficulty maintaining fluid
balance, an effect exacerbated by reductions in the colloid
osmotic pressure gradient. Hypoproteinemia, as a surro-
gate for colloid osmotic pressure, is associated with the
development and maintenance of ARDS, prolonged dura-
tion of mechanical ventilation, and mortality in patients with
sepsis. A RCT of 37 patients with ALI or ARDS has pro-
vided evidence that combined therapy with furosemide
and albumin is effective in augmenting serum albumin and
STP levels, promoting weight loss, acutely increasing oxy-
genation and, despite substantial diuresis and weight loss,
improving longer-term hemodynamic stability. Clinically
important treatment-associated adverse effects were notencountered aside from expected electrolyte changes.
These results support the concept that both hydrostatic
and osmotic forces play pivotal roles in hypoxemic respira-
tory failure. Further studies will be needed to confirm these
findings and evaluate the observed trend toward reduced
duration of mechanical ventilation and length of ICU stay
in patients receiving furosemide and albumin.
Commentary
AB Johan Groeneveld, MD: PaO2/FiO2 ratios are difficult to
interpret outside the context of PEEP levels associated with
mechanical ventilation. Were there any differences in PEEP
between the groups, or in radiographic appearances?
Greg Martin, MD: PEEP is clearly an important factor in
considering oxygen requirements. No between-group dif-
ferences were observed with respect to PEEP at any time,
including the first 2 days of treatment—the period when
oxygenation changed most dramatically. Mean airway
pressure, which correlates moderately with oxygenation,
declined slowly from baseline in both groups without dif-
ference. Daily radiographs did not appear to change sig-
nificantly in the first 2 days, although standard radiographs
are poor indicators of changes in oxygenation and
extravascular lung water, since such changes may not be
immediately observable. Further evaluation of these find-
ings is underway.
William J Sibbald MD: The results of this RCT, particularly
in terms of weight loss and acute increase in PaO2/FiO2
ratio, appear to be conveying a strong biological signal.
Adoption of this treatment approach in the ICU would opti-
mally need to be based upon a demonstration of reduced
need for other healthcare resources such as mechanical
ventilation. It is difficult to see how this might be accom-
plished other than by conducting a larger-scale RCT.
The significant decline in heart rate among diuretic and
albumin recipients was of particular interest. A recent
meta-analysis underscored the difficulties in making a clini-
cal diagnosis of hypovolemia [16]. However, a postural
pulse increment ³30beats/min was a reasonably good
marker for severe but not moderate hypovolemia. Was
PAWP measured in the RCT?
Greg Martin, MD: Yes, but pulmonary artery catheters
were present in approximately one-third of the study
patients. In these patients, no significant differences were
noted with respect to PAWP. The question of healthcare
resources is certainly salient. Detecting a difference in
mechanical ventilation requirements of this magnitude
might require a RCT enrolling more than 200 patients.
Jean-Louis Vincent, MD, PhD: The study population evi-
dently may have included cases of hemodynamic pulmonary
edema as well as of ARDS. Patients with fluid overload
could clearly have benefited from negative fluid balance.
Since PAWP was monitored in <40% of the study patients,
might fluid overload following resuscitation from trauma
have contributed to the observed treatment effects?
Greg Martin, MD: That possibility cannot be excluded,
although in the monitored patients baseline PAWP was in
the 12–14mmHg range, thus providing some assurance
that gross fluid overload was unlikely. As previously
described, PAWP at least intermittently exceeding
18mmHg has been demonstrated in more than 80% of
ARDS patients. Thus, uncertainties regarding fluid over-
load will be inherent in any trial of patients with ARDS.
AB Johan Groeneveld, MD: Under conditions of low
colloid osmotic pressure, threshold hydrostatic pressure is
decreased, so the lungs may be readily susceptible to fluid
overload even with PAWP £16mmHg. This means, in
effect, that there may be pressure-dependent pulmonary
edema at low wedge pressures.
Andrew R Webb, MD: Lymphatic drainage also need to be
taken into account. At lower filling pressures, lymphatic
drainage is greater. Therefore, while the lungs may be pro-
ducing more edema, they are clearing it more quickly as well.
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